Morten O. A. Sommer

Morten O. A. Sommer has extensive experience in the life sciences industry. Morten O. A. began their career in 2006 as the Founder of Microlytic, where they successfully secured VC financing, established US operations and sales force, and commercialized several product lines used to determine over 1000 novel protein structures. In 2008, they became a Research Fellow at Harvard Medical School, where they developed new approaches to drug combination treatment based on computational models of microbial metabolism and elucidated the reservoir of resistance genes harbored by the guy microbiota. In 2010, Morten became a Professor and Scientific Director at the Technical University of Denmark. Morten O. A. then went on to Co-Found Biosyntia in 2012, Medicon Valley Alliance in 2014, Clinical Microbiomics in 2015, SNIPR Biome - A CRISPR Company in 2017, UTILITY therapeutics in 2018, and Novozymes in 2022, where they currently serve as a Board Member. In 2011, Morten Co-Founded UNION therapeutics A/S, a clinical-stage, diversified pharmaceutical company focused on identifying, developing and commercializing treatments for immunology and infectious diseases. Microlytic was sold to Anatrace in 2014.

Morten O. A. Sommer began their educational journey in 2000 when they earned an M.Sc. in Physics and Biophysics from Københavns Universitet - University of Copenhagen. From 2002-2003, they attended Caltech, studying Applied Physics and Microfluidics. Morten O. A. then went on to Harvard University, where they obtained a PhD in Biophysics in 2008.